1. Thiazolidinone/thiazole based hybrids – New class of antitrypanosomal agents
2. Synthesis and anticancer activity evaluation of 3-(4-oxo-2-thioxothiazolidin-5-yl)-1H-indole-carboxylic acids derivatives
3. Mendel D, Laird D, Xin X, Louie S, Christensen J, Li G, Schreck R, Abrams T, Ngai T, Lee T, Murray L, Carver J, Chan E, Moss K, Haznedar J, Sukbuntherng J, Blake R, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington, J. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9(1):327-37.
4. The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties
5. Laird D, Vajkoczy P, Shawver L, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard S, Blake R, Fong A, Strawn L, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth P, McMahon G, Cherrington J. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000; 60(15):4152-60.